Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study
- PMID: 10974429
- DOI: 10.1016/s0306-4522(00)00241-4
Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study
Abstract
Cannabinoid compounds have been reported to excite ventral tegmental neurons through activation of cannabinoid CB1 receptors. More recently, biochemical and whole-cell voltage-clamp studies carried out on CB1-transfected AtT20 cells have shown a rapid desensitization of these receptors following activation of protein kinase C by 4-alpha-phorbol. To investigate the possible physiological correlates of this phenomenon, we have studied the effects of repeated cannabinoid treatment on ventral tegmental area dopaminergic neuronal firing in vitro. Rat brain slices containing the ventral tegmental area were used for single-unit extracellular recordings. Only neurons meeting established electrophysiological and pharmacological criteria for dopaminergic neurons were used in the study (firing neurons were detected either using tungsten or glass microelectrodes). The high-affinity cannabinoid agonist HU210 produced a concentration-dependent increase in firing (1-15 microM; EC(50) approximately 7 microM). Initial HU210 exposure produced a significant increase in cell firing rate in the ventral tegmental area, with a maximum approximately 3.5-fold increase over pre-drug basal firing; a subsequent exposure to HU210 produced an approximately threefold increase over basal firing. Nevertheless, the duration and onset of excitation produced by the cannabinoid differed significantly between the first and second exposures; the first excitation lasted significantly longer than the second and required less time to reach a comparable change in firing rate. The increases in firing rate and the time to return to basal firing were not significantly different between exposures. Furthermore, the cannabinoid antagonist SR141716A completely prevented the HU210-induced excitation whilst having no effect on its own, thus indicating a CB1-receptor mediated mechanism for the observed increase in firing. Ventral tegmental area neurons are also excited by the GABA(A) receptor antagonist bicuculline. To assess the role of GABA in cannabinoid-mediated excitation, HU210 was added in the presence of bicuculline. HU210 did not affect the initial bicuculline-induced increase in firing, suggesting different sites of action for the two compounds. Our data fail to support previously reported findings using repeated cannabinoid administration and cell preparations. The maintained increase in DA drive elicited by the potent cannabinoid agonist HU210 in the in vitro ventral tegmental circuit could explain some of the behavioural properties of cannabinoids, such as the lack of tolerance for the psychotropic effects of marijuana seen in human users.
Similar articles
-
Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum.Neuropharmacology. 2003 Apr;44(5):633-41. doi: 10.1016/s0028-3908(03)00029-7. Neuropharmacology. 2003. PMID: 12668049
-
Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation.Eur J Neurosci. 2001 Jul;14(1):96-102. doi: 10.1046/j.0953-816x.2001.01612.x. Eur J Neurosci. 2001. PMID: 11488953
-
Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids.Eur J Neurosci. 2002 Jun;15(12):2057-61. doi: 10.1046/j.1460-9568.2002.02041.x. Eur J Neurosci. 2002. PMID: 12099913
-
Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.Neuropharmacology. 2005 Jun;48(8):1105-16. doi: 10.1016/j.neuropharm.2005.03.016. Neuropharmacology. 2005. PMID: 15878779 Review.
-
Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:24-7. doi: 10.1016/j.pnpbp.2014.01.019. Epub 2014 Feb 2. Prog Neuropsychopharmacol Biol Psychiatry. 2014. PMID: 24495779 Free PMC article. Review.
Cited by
-
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data.Psychopharmacology (Berl). 2003 Sep;169(2):115-34. doi: 10.1007/s00213-003-1485-z. Epub 2003 Jun 24. Psychopharmacology (Berl). 2003. PMID: 12827346 Review.
-
To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making.Front Behav Neurosci. 2015 Dec 17;9:336. doi: 10.3389/fnbeh.2015.00336. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26733830 Free PMC article. Review.
-
Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments.Curr Neuropharmacol. 2025;23(3):256-275. doi: 10.2174/1570159X22666240827165327. Curr Neuropharmacol. 2025. PMID: 39219428 Free PMC article. Review.
-
A Behavioural and neurobiological assessment of effort-based decision-making in cannabis use disorder: An initial/preliminary investigation.Cogn Affect Behav Neurosci. 2025 Jun 17. doi: 10.3758/s13415-025-01308-x. Online ahead of print. Cogn Affect Behav Neurosci. 2025. PMID: 40528148
-
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.J Neurosci. 2004 May 5;24(18):4393-400. doi: 10.1523/JNEUROSCI.0529-04.2004. J Neurosci. 2004. PMID: 15128853 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources